Prosecution Insights
Last updated: April 19, 2026

Examiner: PATEL, SAGAR S

Tech Center 1600 • Art Units: 1626

This examiner grants 76% of resolved cases

Performance Statistics

75.8%
Allow Rate
+15.8% vs TC avg
485
Total Applications
+33.8%
Interview Lift
976
Avg Prosecution Days
Based on 455 resolved cases, 2023–2026

Rejection Statute Breakdown

1.0%
§101 Eligibility
20.7%
§102 Novelty
32.8%
§103 Obviousness
23.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17093833 OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS Non-Final OA Merck Sharp & Dohme LLC
17618829 AMINO ACID TRANSPORT INHIBITORS AND THE USES THEREOF Final Rejection VANDERBILT UNIVERSITY
18330171 MODULATORS OF THE INTEGRATED STRESS PATHWAY Non-Final OA AbbVie Inc.
18030105 SMALL MOLECULE NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATORS Non-Final OA THE CLEVELAND CLINIC FOUNDATION
18295582 TETRAPYRROLE-BASED COMPOUNDS AND THEIR FOMULATIONS FOR ANTI-MICROBIAL THERAPY Non-Final OA Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
18007296 SELECTIVE PHOSPHATASE INHIBITORS BASED ON ILLUDALIC ACID Non-Final OA WEST VIRGINIA UNIVERSITY BOARD OF GOVERNORS ON BEHALF OF WEST VIRGINIA UNIVERSITY
18453798 COMPOUNDS AND METHODS FOR MODULATING HER2 Non-Final OA Iambic Therapeutics, Inc.
18262326 ANTI-VIRAL AGENT Non-Final OA NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY
18267277 NITROGENOUS HETEROAROMATIC COMPOUNDS FOR ORGANIC ELECTROLUMINESCENT DEVICES Non-Final OA UDC IRELAND LIMITED
18557217 PROCESS FOR PREPARING PEXIDARTINIB Non-Final OA JOHNSON MATTHEY PUBLIC LIMITED COMPANY
17350374 PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULPHUR CONTAINING SUBSTITUENTS Final Rejection SYNGENTA PARTICIPATIONS AG
18263227 CYCLOPROPYLAMIDE COMPOUNDS AGAINST PARASITES IN FISH Non-Final OA Corteva Agriscience LLC
18571386 DAPRODUSTAT FOR REDUCING FATIGUE IN A SUBJECT WITH ANEMIA ASSOCIATED WITH CHRONIC KIDNEY DISEASE Non-Final OA GlaxoSmithKline Intellectual Property (No.2) Limited
18462120 HETEROATOM SUBSTITUTED CYCLIC AND ALKYL AMINES AS ACTIVATORS OF SEROTONIN RECEPTORS Non-Final OA ATAI Therapeutics, Inc.
18211840 NANOMATERIALS COMPRISING CARBONATES Non-Final OA Beam Therapeutics Inc.
18365343 BIPHENYL COMPOUNDS CONTAINING SUBSTITUTED SULFIDE (SULFOXIDE) GROUPS AND USES THEREOF Non-Final OA SHENYANG UNIVERSITY OF CHEMICAL TECHNOLOGY
18030757 Deuterated Camptothecin Derivative And Antibody-drug Conjugate Thereof Non-Final OA Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
18043609 ANTIVIRAL PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION Final Rejection Christian-Albrechts-Universitat Zu Kiel
18020916 SPIRO COMPOUND AND APPLICATION THEREOF Non-Final OA SICHUAN AG-RAY NEW MATERIALS CO., LTD
18004064 SOLID STATE FORMS OF 6-CARBOXY-2-(3, 5-DICHLOROPHENYL)-BENZOXAZOLE OF FORMULA-I AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF Non-Final OA NURAY CHEMICALS PRIVATE LIMITED

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month